You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫藥股普遍跑贏大市 藥明生物、三葉草生物及開拓藥業漲半成
恆指現報20,118,續升150點或約0.7%,總成交額535億元。 醫藥板塊今早(26日)普遍跑贏,藍籌股藥明生物(02269.HK)今早升破10天及20天線(分別69元及70.7元),最高見72.3元,現報71.8元,續升4.9%。藥明康德(02359.HK)也反覆續升2.3%,報90元。 中期虧損收窄的三葉草生物-B(02197.HK)公佈新冠候選疫苗全球II/III期臨牀試驗青少年人羣取得積極數據。該股由上市低位連彈第二天兼挑戰10天線(2.79元),最高見2.84元,現報2.78元,續彈5.3%。 開拓藥業-B(09939.HK)追彈逾5%報17.26元,股價重越50天線(16.75元)。此外,石藥(01093.HK)、君實生物(01877.HK)、復星醫藥(02196.HK)、金斯瑞生物(01548.HK)、信達生物(01801.HK)、威高股份(01066.HK)、百濟神州(06160.HK)、康方生物-B(09926.HK)及聯邦製藥(03933.HK)續升介乎1.5%至3%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account